Pituitary apoplexy: an update on clinical and imaging features

Alessandro Boellis · Alberto di Napoli · Andrea Romano · Alessandro Bozzao

Received: 23 March 2014 / Revised: 8 September 2014 / Accepted: 23 September 2014 / Published online: 16 October 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Pituitary apoplexy (PA) is a rare and potentially fatal clinical condition presenting acute headache, vomiting, visual impairment, ophthalmoplegia, altered mental state and possible panhypopituitarism. It mostly occurs in patients with haemorrhagic infarction of the pituitary gland due to a pre-existing macroadenoma. Although there are pathological and physiological conditions that may share similar imaging characteristics, both clinical and imaging features can guide the radiologist towards the correct diagnosis, especially using magnetic resonance imaging (MRI). In this review, we will describe the main clinical and epidemiological features of PA, illustrating CT and MRI findings and discussing the role of imaging in the differential diagnosis, prognosis and follow-up.

Teaching points

- Headache, ophthalmoplegia and visual impairment are frequent symptoms of pituitary apoplexy.
- CT is often the first imaging tool in PA, showing areas of hyperdensity within the sellar region.
- MRI could confirm haemorrhage within the pituitary gland and compression on the optic chiasm.
- Frequent simulating conditions are aneurysms, Rathke cleft cysts, craniopharyngioma and mucocele.
- The role of imaging is still debated and needs more studies.

Keywords Pituitary apoplexy · Pituitary adenoma · MRI · Pituitary haemorrhage · Macroadenoma

Introduction

Pituitary apoplexy (PA) was first described by Pearce Bailey in 1898 [1] and recognised as a defined clinical syndrome by Brougham et al. in 1950 [2]. It is a severe and potentially fatal medical condition characterised by the variable association of headache, vomiting, visual impairment, ophthalmoplegia, altered mental state and panhypopituitarism [2–5]. The syndrome is often related to haemorrhagic infarction of the pituitary gland, usually in a condition of a pre-existing macroadenoma [6–8] occurring in 1.6 to 2.8% of patients with this neoplasm. In a consistent number of patients with PA, this clinical syndrome represents the first sign of a previously undetected adenoma. Few cases of apoplexy have been reported in patients without a previous pituitary pathology [9, 10] such as Sheehan syndrome, a condition characterised by pituitary infraction occurring in post- or peripartum females with hypovolaemia [11–13].

The diagnosis of PA can be made only when haemorrhagic infarction of the pituitary gland leads to the previously described clinical syndrome; the use of the term PA should be avoided in asymptomatic patients. In fact, huge haemorrhages can be a common finding in patients with macroadenomas without PA symptoms [14, 15].

Many clinical series of patients with PA have been reported, while its imaging features are less frequently described. Because of the potential severe prognosis of PA, radiologists should be aware of its imaging characteristics on both computed tomography (CT) and magnetic resonance imaging (MRI), being able to recognise the main conditions that may mimic PA, from a clinical and radiological perspective.

Definition, clinical features and pathogenesis

Based on the above-mentioned clinical definition, PA is a rare event and occurs in 1.6 to 2.8% of patients with
macroadenomas; it is more frequent in males, with a gender ratio of 2:1 and a mean age of onset of 57 years [5, 16–18]. About 60% of patients with PA may not be aware of having a pituitary adenoma before the acute event.

Pituitary apoplexy has a wide spectrum of clinical manifestations; based on many reports, the most common symptom is headache, with an incidence of 90–97% [2–5, 19]. This is often described as a sudden, severe head pain, frequently retro-orbital in location [20], that includes PA into the differential diagnosis of a condition known as “thunderclap headache”. This comprehends important and more frequent diseases such as subarachnoid haemorrhage, cerebral venous sinus thrombosis or cervical artery dissection [21].

The second most frequent symptom is the visual deficit, ranging from 50 to 82% of cases [5, 13, 20–25], followed by nausea, vomiting, ocular palsy and meningism (25–50%).

Many authors described that PA is strictly associated with a sudden enlargement of a pre-existing pituitary adenoma, resulting in a disturbance of the residual pituitary function and local mass effect on surrounding structures or, less frequently, in a sudden increase of intracranial pressure [5, 16, 26–28]. Meningeal irritation occurs if blood gains access to the suprasellar cisterns through a dilated diaphragm sellae [5].

Many known factors predispose patients to symptomatic infarction of the pituitary, amongst which the most important are hypertension [10, 20], diabetes mellitus [29], pituitary function dynamic tests [30, 31], administration of anticoagulants, bromocriptine, oestrogens [32–34] and radiotherapy [35]. The pathogenesis underlying pituitary apoplexy is still unknown. A possible mechanism can be the subacute, excessive growth of the pre-existing adenoma, which outgrows its blood supply with eventual ischaemic necrosis followed by haemorrhage [2, 35]. Indeed, pathologic and dynamic imaging studies [36, 37] have shown that macroadenomas, as well as microadenomas, are less vascularised than the pituitary gland, so that a relatively fast and sizable growth can exceed this low blood supply. However, this theory does not explain the onset of PA in patients with small adenomas or with a healthy pituitary. Another hypothesis is that tumour compression of the infundibulum and superior pituitary arteries may cause infarction of the normal pituitary gland; however, ischaemia of the tumour mass itself is less probable in this case because the vessels supplying the adenoma are attributable to the inferior pituitary circulation [38]. Therefore, pituitary tumours probably suffer from an intrinsic vasculopathy that can lead to spontaneous infarction and haemorrhage [4, 22, 23, 39].

**Imaging findings**

**Computed tomography**

Most of the patients with symptoms related to PA will undergo computed tomography (CT) in an emergency setting. It is likely that, in most of them, the clinical suspicion might something other than PA. CT is effective in visualising pituitary expansive lesions leading to sellar enlargement (up to 94% of cases) [5, 20, 25]. Because of the haemorrhagic component in most of PAs, CT will show patchy or confluent areas of hyperdensity within a pituitary lesion (Fig. 1) [5, 14, 20, 25]. Although a hyperdense lesion inside the sella turcica tends to represent PA in the proper clinical setting, diseases other than PA may lead to similar radiological pictures. The

![Fig. 1 CT appearance of pituitary apoplexy. Arrows on axial (a), coronal (b) and sagittal (c) reconstructions indicate an intrasellar lesion, dis-homogeneously hyperdense, due to the presence of haemorrhagic components. The utility of reformatted images in the evaluation of the intrasellar hyperdensity is evident](image-url)
most common hyperdense lesions in the pituitary region are aneurysms, meningiomas, Rathke cleft cysts, germinomas and lymphoma. They can be easily differentiated from blood using MRI. After administration of contrast medium, a rim of enhancement may be the sign of pituitary apoplexy [40]. The real accuracy of CT in the diagnosis of PA is not fully described, being dependent on the time of imaging from onset of symptoms and on technical characteristics of CT itself. Some authors demonstrated a low sensitivity of CT in detecting pituitary tumour haemorrhage; this ranges from 21 % [20] to 46 % [16]. A possible explanation for these wide ranges is related to blood degradation, leading to a decreased density, in the days following the acute onset. For this reason, making the distinction between cystic or degenerative changes inside a pituitary neoplasm and a subacute haemorrhage may be impossible [14]. Based of the above-mentioned data, it is important to remember that the CT examination may be normal, underestimated or non-pathognomonic, especially in those rare patients with non-haemorrhagic PA or without a pre-existing pituitary adenoma. Therefore, although CT can exclude other diseases (i.e. subarachnoid haemorrhage), an MR examination can give more details about a suspected PA [14, 20].

Magnetic resonance imaging

Magnetic resonance imaging (MRI) is the most important tool in the diagnosis of PA, being able to identify the presence of an adenoma and its haemorrhagic degeneration. MRI is definitely superior to CT in the diagnosis of PA with a sensitivity ranging from 88 % to 90 % [18, 41]. Recently, Semple et al. demonstrated that MRI features of PA correlate with the
pathologic reports and operative findings and that PA features can be accurately predicted from MR imaging [14].

It is well known that the signal of blood clots in MRI changes over time. In the acute phase (0–7 days), deoxyhaemoglobin leads to shortening of the T2 relaxation time due to the susceptibility effect and the MRI signal is hypointense on T2-weighted imaging (T2WI) with isointensity or slight hypointensity on T1-weighted imaging.

**Fig. 3** Large pituitary macroadenoma with MRI signs of subacute haemorrhage. In this phase, haemorrhage appears hyperintense on both T1WI (b) and T2WI (a). In the T2WI (a, e), thickening of the sphenoid mucosa (arrow) is evident as well. This sign is highly specific for pituitary apoplexy. On contrast-enhanced MRI (c, d, f) the residual pituitary gland enhances (arrow in c compared to b). Note the optic pathway compression, more evident on T2WI.

**Fig. 4** The figure shows an oval-shaped, haemorrhagic lesion within a pituitary adenoma, homogeneously hyperintense on both T1- and T2-weighted images (WI) (a), with a hypointense rim on T2WI (b, white arrow). Contrast-enhanced T1WI (c) shows strong, homogeneous enhancement of the pituitary gland and stalk, both displaced by the tumour.
In the subacute phase (7–21 days), methaemoglobin shortens the T1 relaxation time and the haemorrhage will appear hyperintense on T1WI as well as on T2WI (Figs. 3 and 4). In the chronic phase (>21 days), macrophages digest the clot and the presence of haemosiderin and ferritine causes a strong hypointensity on both T1WI and T2WI [42–44].

First, Poitin et al. and, more recently, Dubuisson et al. described the MRI features in a group of patients with PA [5, 45]. MRI predominantly showed an intra- and suprasellar expanding mass with different signal intensities on T1WI and T2WI, depending on the presence of haemorrhage and on its stage, as described above. In most cases, MRI performed during the acute phase of the clinical syndrome shows areas of hyperintensity on T1WI, generally more pronounced in the peripheral area of the lesions [45]. After IV gadolinium administration, a slight and inhomogeneous contrast enhancement is evident (Figs. 3c, f, 4) but often is difficult to differentiate from normal residual pituitary gland [5, 14, 45, 46]. T2WI showed areas of mixed high and low signal intensity, with the presence of a possible thin peripheral ring of marked hypointensity, representing haemosiderin and ferritin deposition. The latter must be considered an unusual and unexpected finding, since pituitary tumours lack a blood-brain barrier, and the accumulation of macrophages containing haemosiderin normally does not occur [45]. T2WIs are even useful in the evaluation of potential compressions of the optic chiasm and hypothalamus by the tumour [40].

Many authors [5, 14, 45] described the possibility of a fluid debris level within the mass. Poitin et al. made a pathological-radiological correlation in their patients with this finding, showing that the upper fluid (hyperintense on T1WI) contains free extracellular meta-Hb and the lower layer (isohypointense on T1WI) corresponds to a sediment of red blood remnants [45]. This finding is suggestive of late subacute haemorrhage and is considered a specific sign of pituitary apoplexy [45–47].

Another important MRI finding that is highly indicative of PA is the thickening of sphenoid sinus mucosa (Fig. 3a) [14, 46, 48]. This condition may be related to venous engorgement in this region, a reversible condition on follow-up studies [14].
Thus, this is considered a specific finding of the acute phase of haemorrhage.

Less is known about the MRI appearance of pituitary apoplexy without haemorrhagic infarction. Ostrov et al. found that this condition may appear as low signal intensity on both T1WI and T2WI, without contrast enhancement inside the lesion but with a peripheral rim of enhancement [49]. It has been reported that diffusion-weighted images may help to visualise areas of infarction within a non-haemorrhagic pituitary lesion [15] but obtaining good DWI images in the pituitary region is challenging because of susceptibility artefacts.

The use of T2*-weighted gradient-echo (GE) MR imaging is currently the most sensitive neuroimaging technique for the identification of brain haemorrhage. T2*-weighted images are highly sensitive to the paramagnetic effects of deoxy-HB and meta-HB and show bleeding products and haemosiderin deposits as areas of strongly hypointense signal. Tosaka et al. recently demonstrated that this statement could be applied even to PA [50]. GE MR can depict acute and chronic haemorrhages not seen with conventional SE techniques. These can appear as a hypointense rim, mass, spot or diffused area of lower signal intensity. The latter, diffused, is related to pituitary adenomas without a history of headache or clinical PA.

Differential diagnosis

MRI is a useful tool in the differential diagnosis of pituitary apoplexy. Many conditions can present with hyperintensity on T1WI in the sellar region, the most frequent MRI feature of PA [46]. Thus, it is important to use advanced MRI techniques such as T2*GE together with a careful search for specific radiological findings, such as fluid levels or thickening of the sphenoid mucosa.

The posterior lobe of the pituitary gland usually appears as a hyperintense spot on T1WI because of storage of vasopressin [51–53]; this is a normal finding and should not be confused with a haemorrhage within the gland.

In the case of anterior pituitary lobe hyperactivity, the gland may be hyperintense [54, 55]. In these cases, haemorrhage can be easily excluded with the evaluation of T2WI and T2*WI.

Another condition to consider for the differential diagnosis is the presence of an aneurysm (Fig. 5). Aneurysms arising from the carotid siphon or from the anterior communicating artery usually appear as round lesions, hypointense on T2WI.

![Fig. 6 Suprasellar RCC appears hyperintense on T1WI (a, b) without contrast enhancement (d). On coronal T2WI (c), an arrow indicates an intracystic hypointense nodule, a typical sign of RCC, related to proteinaceous concretion. MR angiography (e) can be useful to rule out the possibility of an aneurysm, but the cyst will appear mildly hyperintense on MIP reconstruction.](image)
because of flow void. Partially thrombosed aneurysm in the sellar region can show high signal intensity on T1WI. Thus, an imaging study should be completed with MR angiography, which is best with a contrast-enhanced technique, to exclude this pathology.

Rathke cleft cysts (RCCs) occur with T1 hyperintensity because of the variable protein content (Fig. 6). RCC, which can be either intra- or suprasellar, is usually located along the midline and does not present a fluid debris level. A hypointense intracystic nodule on T2WI, related to concretion of proteinaceous material within the RCC, is typical (Fig. 6c). The variable MRI appearance of RCC may cause difficulties in the differential diagnosis with PA. Moreover, a large suprasellar RCC may mimic PA even clinically, with acute onset of headache and visual deficit, as described by the recent work of Binning et al.

Craniopharingioma is another pathology that can be difficult to distinguish from PA. It is usually an intra-/suprasellar lesion with variable solid, cystic and calcified components. The cystic component may contain a proteinaceous fluid, appearing hyperintense on T1WI, and mimicking haemorrhagic degeneration. Careful evaluation of T2WI together with the acquisition of a CT scan to rule out calcific components can help to obtain the correct diagnosis.

Other conditions that can simulate PA on imaging are lipoma, dermoid cysts and postoperative changes. Lipoma and dermoid cysts contain fat and can be confirmed with fat-suppressed images. Anyway, these pathologies do not usually appear with the clinical syndrome of PA.

**Role of imaging in prognosis, therapy and follow-up**

In clinical practice, many endocrinologists and pituitary surgeons believe that patients presenting with ophthalmoplegia (typically III palsy) without visual field loss may safely be monitored conservatively—typically with spontaneous full recovery of the ophthalmoplegia after several weeks and very often with substantial shrinkage of the pituitary mass on the follow-up scan some months later.

The role of imaging, in particular of MRI, in the decision-making process for a proper therapy is still debated and
probably needs more study. Some authors reported that MRI findings in patients with PA do not correlate with the severity of its clinical presentation, in terms of both visual loss and cranial nerve palsies \[25, 45, 50\], suggesting that the role of imaging might be limited. Despite this, in the series of Ayuk and colleagues, patients undergoing MRI were managed more safely with conservative treatment because of identification of areas of haemorrhage and infarction, which on repeated MRI scanning allows prediction of the evolution of PA \[25\]. Semple et al. recently described that patients with PA and MRI findings of pituitary infarction without signs of haemorrhage showed a less severe clinical presentation and a better outcome \[14\].

Although no study demonstrated that chiasm compression may represent the most relevant MRI feature, it is likely that this observation has a clinical impact in the decision-making process (Fig. 3).

For the above-mentioned reasons, even though the most important features for treatment decisions (surgical or conservative) are related to the severity of the clinical condition \[59\], MRI can offer relevant prognostic information (Figs. 3 and 7).

The recent UK guidelines for the management of PA indicate an urgent MRI in patients with suspected PA as IIIB evidence class, since more randomised clinical trials are required. If MRI is contraindicated, a dedicated pituitary multidetector CT is advisable \[59\].

Radiological follow up with MRI in patients affected by PA is important. The pre-existing adenoma might grow after bleeding and eventually re-bleed (Fig. 8) \[20\]. In those patients treated conservatively, tumour growth after bleeding occurs within a wide range, as shown by different studies (from 6 to 90 %), but this indicates the need for clinical radiological follow-up 3–6 months after PA and every year for at least 5 years. Recurrent pituitary apoplexy has been documented in studies with both conservative and surgically therapeutic approaches, without a significant difference in the incidence between these groups \[25, 60\].

**Conclusions**

PA is a severe clinical syndrome and imaging is important to rule out other pathologies showing similar symptoms.

Currently, CT is the most commonly used imaging modality during the acute onset of symptoms consistent with PA. Despite this, CT lacks sensitivity and MRI should always be performed if PA is suspected. MRI can evaluate pituitary infarct and haemorrhage, mass effect and differentiate PA.
from other pathologies such as a Rathke cleft cyst or craniopharingioma. Other MR techniques such as MRA, DWI and T2*-weighted GE images can increase its diagnostic capabilities.

Although more studies will be necessary to define the role of MRI in treatment choices and prognostic information, this modality is a fundamental step in the diagnosis of PA in the acute phase and is mandatory in the follow-up of these patients.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Bailey P (1898) Pathological report of a case of acromegaly with special reference to the lesions in hypophysis cerebri and in the thyroid gland, and a case of hemorrhage into the pituitary. Phila Med J 1:789–792
2. Brougham M, Heusner AP, Adams RD (1950) Acute degenerative changes in adenomas of the pituitary body—with special reference to pituitary apoplexy. J Neurosurg 7:421–439
3. Wakai S, Fukushima T, Teramoto A, Sano K (1981) Pituitary apoplexy: its incidence and clinical significance. J Neurosurg 55:187–193
4. Cardoso ER, Peterson EW (1984) Pituitary apoplexy: a review. Neurosurgery 14:363–373
5. Dubuisson AS, Beckers A, Stevenaert A (2007) Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. Clin Neurol Neurosurg 109:63–70
6. Ebersold MJ, Laws ER, Scheithauer BW, Randall RV (1983) Pituitary apoplexy treated by transphenoidal surgery. A clinicopathological and immunocytochemical study. J Neurosurg 58:315–320
7. Mohr G, Hardy J (1983) Haemorrhage, necrosis and apoplexy in pituitary adenomas. Surg Neurol 18:181–189
8. Rovit RL, Fein JM (1972) Pituitary apoplexy: a review and reappraisal. J Neurosurg 37:280–288
9. Conomy JP, Ferguson JH, Brodkey JS, Mitsumoto H (1975) Spontaneous infarction in pituitary tumours. Neurologic and therapeutic aspects. Neurology 25:580–587
10. Reid R, Quigley ME, Yen SSC (1985) Pituitary apoplexy: a review. Arch Neurol 42:712–719
11. Lavallée G, Morcos R, Palaridy J, Aubé M, Gilbert D (1995) MR of nonhemorrhagic postpartum pituitary apoplexy. AJNR 16:1939–1941
12. Sheehan HL, Stanfor JP (1961) The pathogenesis of postpartum pituitary necrosis of the anterior lobe of the pituitary gland. Acta Endocrinol 37:479–510
13. Couture N, Aris-Jilwan N, Serri O (2012) Apoplexy of microprolactinoma during pregnancy: case report and review of literature. Endocr Pract 18(6):e147–e150
14. Semple PL, Jane JA, Lopes MBS, Laws ER (2008) Pituitary apoplexy: correlation between magnetic resonance imaging and histopathological results. J Neurosurg 108:909–915
15. Rogg JM, Tung GA, Anderson G, Cortez S (2002) Pituitary apoplexy: early detection with diffusion-weighted MR imaging. AJNR Am J Neuroradiol 23:1240–1245
16. Bills DC, Meyer FB, Laws ER et al (1993) A retrospective analysis of pituitary apoplexy. Neurosurgery 33(4):602–609
17. Fraioli B, Esposito V, Palma L, Cantore G (1990) Hemorrhagic pituitary adenomas: clinicopathological features and surgical treatment. Neurosurgery 27(5):741–748
18. Onesti ST, Wisniewski T, Post KD (1990) Clinical versus subclinical pituitary apoplexy: presentation, surgical management and outcome in 21 patients. Neurosurgery 26(6):980–986
19. Pant B, Arita K, Kurisu K, Tominaga A, Eguchi K, Uozumi T (1997) Incidence of intracranial aneurysm associated with pituitary adenoma. Neurosurg Rev 20:13–17
20. Randeva H, Schoebel J, Byrne J, Esiri M, Adams C, Wass J (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol 51:181–188
21. Schwedt T, Matharu M, Dodick D (2006) Thunderclap headache. Lancet Neurol 5:621–631
22. Shahlaie K, Olaya J, Hartman J, Watson JC (2006) Pituitary apoplexy associated with anterior communicating artery aneurysm and aberrant blood supply. J Clin Neurosci 13:1057–1062
23. Mortimer AM, Bradley MD, Stooldy NG, Renowden SA (2013) Thunderclap headache: diagnostic considerations and neuroimaging features. Clin Radiol 68:e101–e113
24. Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawa J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency. Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir 120:118–122
25. Ayuk J, McGregor EJ, Mitchell RD, Gottes NL (2004) Acute management of pituitary apoplexy—surgery or conservative management? Clin Endocrinol 61:747–752
26. Chacko AG, Chacko G, Seshadri MS, Chandy MJ (2002) Hemorrhagic necrosis of pituitary adenomas. Neurol India 50:490–493
27. Chanson P, Lepeintre JF, Ducruix D (2004) Management of pituitary apoplexy. Expert Opin Pharmacother 5:1287–1298
28. De Villiers JC, Marcus G (1988) Non-haemorrhagic infarction of pituitary tumours presenting as pituitary apoplexy. Adv Biosci 69:461–464
29. Brennan CF, Malone RGS, Weaver JA (1956) Pituitary necrosis in diabetes mellitus. Lancet 271:12–16
30. Chapman AJ, Williams G, Hockley AD, London DR (1956) Pituitary apoplexy after combined tests of anterior pituitary function. Br Med J 291:26
31. Arafah BM, Harrington JF, Madhoun ZT, Selman WR (1990) Hemorrhagic necrosis of pituitary adenomas. Adv Biosci 69:–320
32. David M, Philippon J, Navarro-Artiles G, Radacot J, Weil BB (1996) Les formes hémorragiques des adénomes hypophysaires: aspects cliniques et étiologiques. Neurochirurgie 15:228–229
33. Yamaji T, Ishibashi M, Kosaka K et al (1981) Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol 98:171–177
34. Nourizadeh AR, Pitts FW (1965) Haemorrhage into pituitary adenoma during anticoagulant therapy. J Am Med Assoc 193:623–624
35. Uhlenin A, Balfour WM, Donovan PF (1957) Acute haemorrhage into pituitary adenoma, and a case of hemorrhage into the pituitary. Phila Med J 792–915
36. Pergolizzi RS, Nabavi A, Schwartz RB et al (2001) Intra-operative angiographic findings in pituitary adenomas. Eur Radiol 15:543–548
37. Powell DF, Baker HL Jr, Laws ER Jr (1974) The primary angiographic findings in pituitary adenomas. Radiology 110:595–596
38. Pia HV, Obrador S, Martin JG (1972) Association of brain tumours and arterial intracranial aneurysms. Acta Neurochir 27:189–204
40. Osborn AG (1972) Pituitary apoplexy. In: Osborn A, Salzman KL, Barkovich AJ (eds) Diagnostic imaging. Brain, 2nd edn. Amirsys Inc, Salt Lake City, II-2-28-31
41. Kaplan B, Day AL, Quisling R, Ballinger W (1983) Haemorrhage into pituitary adenomas. Surg Neurol 20:280–287
42. Bradley WG (1993) Appearance of hemorrhage in the brain. Radiology 189:15–26
43. Hardy PA, Kucharczyk W, Henkelman RM (1990) Cause of signal loss in MR images of old hemorrhagic lesions. Radiology 174:549–555
44. Jones KM, Mulkern RV, Mantello MT et al (1992) Brain hemorrhage: evaluation with fast spin-echo and conventional dual spin-echo images. Radiology 182:53–58
45. Piotin M, Tampieri D, Rüfenacht DA et al (1999) The various MRI patterns of pituitary apoplexy. Eur Radiol 9:918–923
46. Bonneville F, Cattin F, Marsot-Dupuch K, Dormont D, Bonneville JF, Chiras J (2006) T1 signal hyperintensity in the sellar region: spectrum of findings. Radiographics 26:93–113
47. Kurihara N, Takahashi S, Higano S et al (1998) Haemorrhage in pituitary adenoma: correlation of MR imaging with operative findings. Eur Radiol 8:971–976
48. Arita K, Kurisu K, Tominaga A et al (2001) Thickening of sphenoid sinus mucosa during the acute stage of pituitary apoplexy. J Neurosurg 95:897–901
49. Ostrov SG, Quencer RM, Hoffman JC, Davis PC, Hasso AN, David NJ (1989) Hemorrhage within pituitary adenomas: how often associated with pituitary apoplexy syndrome? Am J Roentgenol 153:153–160
50. Tosaka MN, Sato J, Hirato H et al (2007) Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging. Am J Neuroradiol 28:2023–2029
51. Fujisawa I, Nishimura K, Asato R et al (1987) Posterior lobe of the pituitary in diabetes insipidus: MR findings. J Comput Assist Tomogr 11:221–225
52. Kurokawa H, Fujisawa I, Nakano Y et al (1998) Posterior lobe of the pituitary gland: correlation between signal intensity on T1-weighted MR images and vasopressin concentration. Radiology 207:79–83
53. Fujisawa I, Kikuchi K, Nishimura K et al (1987) Transection of the pituitary stalk: development of an ectopic posterior lobe assessed with MR imaging. Radiology 165:487–489
54. Cox TD, Elster AD (1991) Normal pituitary gland: change in shape, size, and signal intensity during 1st year of life at MR imaging. Radiology 179:721–724
55. Miki Y, Asato R, Okamura R et al (1993) Anterior pituitary gland in pregnancy: hyperintensity at MR. Radiology 187:229–231
56. Hayashi Y, Tachibana O, Muramatsu N et al (1999) Rathke cleft cyst: MR and biomedical analysis of cyst content. J Comput Assist Tomogr 23:34–38
57. Binning MJ, Liu JK, Gannon J, Osborn AG, Couldwell WT (2008) Hemorrhagic and nonhemorrhagic Rathke cleft cysts mimicking pituitary apoplexy. J Neurosurg 108:3–8
58. Pusey E, Kortman KE, Flannigan BD, Tsuruda J, Bradley WG (1987) MR of craniopharyngiomas: tumor delineation and characterization. Am J Roentgenol 149:383–388
59. Rajasekaran S, Vanderpump M, Baldeweg S (2011) UK guidelines for the management of pituitary apoplexy. Clin Endocrinol 74:39–45
60. Gruber A, Clayton A, Kumar S, Robertson I, Howlett TA, Mansell P (2006) Pituitary apoplexy: retrospective review of 30 patients—is surgical intervention always necessary? Br J Neurosurg 20:379–385